Northern Trust Corp Outlook Therapeutics, Inc. Transaction History

Northern Trust Corp

$600 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$0.22 - $0.66 $25,809 - $77,427	117,314 Added 9.34%	1,373,651 $535,000
Q3 2023 Nov 13, 2023	BUY	$0.2 - $1.78 $207 - $1,844	1,036 Added 0.08%	1,256,337 $276,000
Q2 2023 Aug 11, 2023	BUY	$1.02 - $1.89 $53,972 - $100,007	52,914 Added 4.4%	1,255,301 $2.18 Million
Q1 2023 May 15, 2023	BUY	$1.0 - $1.35 $256,191 - $345,857	256,191 Added 27.08%	1,202,387 $1.31 Million
Q4 2022 Feb 13, 2023	SELL	$0.87 - $1.33 $26,228 - $40,096	-30,148 Reduced 3.09%	946,196 $1.02 Million
Q3 2022 Nov 14, 2022	BUY	$1.02 - $1.26 $1,471 - $1,818	1,443 Added 0.15%	976,344 $1.19 Million
Q2 2022 Aug 12, 2022	SELL	$0.91 - $2.01 $5,991 - $13,233	-6,584 Reduced 0.67%	974,901 $995,000
Q1 2022 May 13, 2022	BUY	$1.22 - $2.03 $200,006 - $332,798	163,940 Added 20.05%	981,485 $1.75 Million
Q4 2021 Feb 08, 2022	SELL	$1.27 - $2.23 $22,572 - $39,636	-17,774 Reduced 2.13%	817,545 $1.11 Million
Q3 2021 Nov 15, 2021	SELL	$2.12 - $2.76 $95,631 - $124,500	-45,109 Reduced 5.12%	835,319 $1.81 Million
Q2 2021 Aug 13, 2021	BUY	$1.78 - $2.76 $1.26 Million - $1.95 Million	706,934 Added 407.47%	880,428 $2.19 Million
Q1 2021 May 12, 2021	BUY	$0.94 - $3.31 $73,829 - $259,974	78,542 Added 82.72%	173,494 $390,000
Q4 2020 Feb 11, 2021	SELL	$0.7 - $1.58 $4,690 - $10,587	-6,701 Reduced 6.59%	94,952 $123,000
Q3 2020 Nov 16, 2020	BUY	$0.61 - $1.6 $16,690 - $43,779	27,362 Added 36.83%	101,653 $73,000
Q2 2020 Aug 14, 2020	BUY	$0.56 - $1.41 $24,090 - $60,656	43,019 Added 137.56%	74,291 $96,000
Q1 2020 May 14, 2020	BUY	$0.51 - $1.08 $15,948 - $33,773	31,272 New	31,272 $19,000

Others Institutions Holding OTLK

# of Institutions

Shares Held

31.5K

Call Options Held

Put Options Held

View Full List

About Outlook Therapeutics, Inc.

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.17B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

More about OTLK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account